Terizidone
Terizidone is a cycloserine derivative used in the treatment of tuberculosis. It is a second-line antitubercular agent, used in combination with other drugs in the treatment of drug-resistant forms of the disease.
Pharmacology[edit]
Terizidone is a prodrug of cycloserine, which is an antibiotic that inhibits cell-wall synthesis in Mycobacterium tuberculosis. It is bacteriostatic and works by inhibiting the synthesis of peptidoglycan, a component of the bacterial cell wall. This action disrupts the cell wall, leading to bacterial cell death.
Clinical Use[edit]
Terizidone is used in the treatment of multi-drug resistant tuberculosis (MDR-TB). It is typically used in combination with other second-line drugs, such as ethionamide, capreomycin, and ofloxacin. The use of terizidone is recommended by the World Health Organization for the treatment of MDR-TB.
Side Effects[edit]
The most common side effects of terizidone include nausea, vomiting, abdominal pain, and rash. More serious side effects can include neurotoxicity, which can manifest as headache, dizziness, confusion, and seizures.
History[edit]
Terizidone was first synthesized in the 1960s as a derivative of cycloserine. It was developed as part of a search for more effective and less toxic antitubercular agents.
See Also[edit]
| 🦠 | This tuberculosis related article is a stub. You can help WikiMD by expanding it. |
